Tharsus Group, the Blyth-based collaborative manufacturing specialist, is supporting the commercialisation of a ground-breaking medical equipment sterilisation technology, on behalf of EnXray.
The technology will enable Medical Equipment Manufacturers to sterilise medical devices at the point of production, which will dramatically reduce cost and improve efficiency within the healthcare industry.
Currently, devices go through a process of ‘terminal sterilisation’ where products are shipped to a third-party for the process to be carried out before they are returned to the manufacturer for verification. This can add up to two weeks to the production process and significant costs to individual businesses.
EnXray founders, Dr Sergey Mitko, Dr Yuri Udalov and Edward Cappabianca, have developed a patented technology to challenge this time consuming process that generates high voltage, low energy x-rays to achieve the kilogray dosage of ionizing radiation needed to ensure that devices can be deemed sterile.
EnXray is a UK medical technology start-up founded in 2012. The company is commercialising its technology for sterilisation of medical devices and life science products, with the goal of developing, producing and distributing equipment for in-house sterilisation.
Tharsus Group has signed a development partnership agreement with EnXray to produce a prototype device and subsequently deploy the commercial device across the medical technology sector.
Tharsus Group’s position as an early adopter of the Original Equipment Design and Manufacture (OEDM) outsourcing service model which includes; product design, development and contract manufacture, will enable it to take the product from initial concept through to scaled production in the shortest possible time.
Brian Palmer, Chief Executive of Tharsus Group, said: “This is a ground-breaking innovation that will have a significant impact on the way medical equipment is manufactured.
“Tharsus will tackle the complexities that come with the realisation of EnXray’s latest innovation, mitigating risk and generating a commercially successful product based on the company’s Intellectual Property.
“Our knowledge-based approach to new product creation enables our engineers to realise EnXray’s insight into its market, which will deliver a scalable system that will be manufactured for the global medical industry.”
Edward Cappabianca, co-founder of EnXray, said: “Partnering with Tharsus is a significant element of the evolution of our expertise in medical sterilisation. Their specialism in the commercialisation of high value, electro-mechanical products will help us bring a new solution in the med-tech field that will meet the requirements of medical device OEMs.”